Production (Stage)
AEON Biopharma, Inc.
AEON
$0.84
-$0.02-2.33%
AMEX
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 18.87% | -13.63% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -30.29% | 41.09% | |||
| Operating Income | 30.29% | -41.09% | |||
| Income Before Tax | 336.84% | 133.74% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 336.84% | 133.74% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 336.84% | 133.74% | |||
| EBIT | 30.29% | -41.09% | |||
| EBITDA | 30.34% | -41.39% | |||
| EPS Basic | -39.24% | 133.41% | |||
| Normalized Basic EPS | 121.22% | -9.42% | |||
| EPS Diluted | -34.13% | 130.08% | |||
| Normalized Diluted EPS | 121.26% | -9.21% | |||
| Average Basic Shares Outstanding | 618.91% | 1.00% | |||
| Average Diluted Shares Outstanding | 617.61% | 1.18% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||